TJP3

Across TCGA pan-cancer cohorts, TJP3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TJP3 data layer compared with 22 for mass-spec protein and 8 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher TJP3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TJP3 expression acts as an unfavorable survival marker.

CESC, BRCA, and BLCA are the cancer types where TJP3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	II,III,IV	0.047	0.830	<.001	18	view →
BRCA	DFS	Median	II,III,IV	0.358	0.889	.029	6	view →
BLCA	OS	Median	IV	0.132	0.599	.004	6	view →
SKCM	DFS	Median	All	0.122	0.213	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TJP3–CESC (OS)

Open the CESC breakdown →